Arachnoiditis Companies

Latest Arachnoiditis Companies Update

• 
  May 2023: Astellas Pharma, the foremost provider of treatments for tinea versicolor in Japan, has reached an agreement to acquire Iveric Bio Inc., a pharmaceutical based in the United States, for approximately $5.9 billion. This acquisition will grant Astellas Pharma access to a variety of ophthalmology treatments. Astellas, the third largest pharmaceutical company in Japan based on sales, has completed its fifth significant international acquisition since 2019 in an effort to secure a stronger pipeline as patent protection expires on its primary products. According to data from Refinitiv, it ranks as the second-largest cross-border acquisition for a Japanese pharmaceutical company in the last five years, after the $6 billion purchase of the psoriasis drug unit of Nimbus Therapeutics by Takeda Pharmaceutical Co., which was announced in December. 

• 
  November 2023: Bayer and Recursion Pharmaceuticals announced in November 2023 that they were shifting the focus of their collaboration from net sales royalties and milestone payments to oncology with the intention of advancing up to seven programs. Recursion could receive a total of $1.5 billion in potential payments. Concurrently, Recursion disclosed that it has entered into a $160 million, five-year agreement with Tempus in exchange for preferred access to over 20 petabytes of data. This data includes patient-centric oncology datasets that are de-identified and comprise patient health records, DNA, and RNA. In addition, Recursion declared that it was augmenting the compute capacity of its BioHive-1 on-premise supercomputer by a factor of four by acquiring over 500 NVIDIA H100 Tensor Core GPUs, in addition to the 300 A100 Tensor Core GPUs that were already operational at the organization. This expansion was intended to support this collaboration and others.

• Baxter


• B. Braun Melsungen AG


• Pfizer Inc.


• SR Pharma


• Abbott


• AstraZeneca


• Bristol-Myers Squibb Company


• DuPont


• Sandoz International GmbH


• Takeda Pharmaceutical Company Limited


• Novartis AG